Results 151 to 160 of about 28,674 (272)

Virtual Screening and ADMET Studies of Phytomolecules Targeting DNA Topoisomerase II

, 2017
Yogesh Kumar, Feroz Khan, Laiq ur Rahman
openalex   +1 more source

Inhibition of DNA Topoisomerases I and II and Cytotoxicity of Compounds from Polygonum aviculare L . [PDF]

, 2021
Yue Yu, Xue-dan Zheng, Meng-hua Piao, Yiming Wang, Li Gao, Mei Jin, Mingshan Zheng   +6 more
openalex   +1 more source

Antibiotic Resistance, Biofilm Genes, and smeDEF Efflux Pump in Clinical Stenotrophomonas maltophilia Isolates From Iran

MicrobiologyOpen, Volume 15, Issue 1, February 2026.
Iranian clinical Stenotrophomonas maltophilia isolates showed high susceptibility to trimethoprim/sulfamethoxazole, minocycline, and levofloxacin, but marked resistance to ceftazidime and ticarcillin‐clavulanate, alongside widespread biofilm production and resistance genes.
Haneen Fadhil Jasim, Nisreen Salah Majeed, Asmaa A. Salam, Rania Hameed Hamad, Yeganeh Behrouzi, Erta Rajabi, Razieh Shahbazi   +6 more
wiley   +1 more source

Synthesis and biological evaluation of 6-substituted indolizinoquinolinediones as catalytic DNA topoisomerase I inhibitors

, 2015
Lemao Yu, Xiaoru Zhang, Xiaobing Li, Yuan Yang, Hongyu Wei, Xixin He, Lian‐Quan Gu, Zhi‐Shu Huang, Yves Pommier, Lin‐Kun An   +9 more
openalex   +1 more source

Oncofetal HMGA2 attenuates genotoxic damage induced by topoisomerase II target compounds through the regulation of local DNA topology [PDF]

, 2019
Syed Moiz Ahmed, Peter Dröge
openalex   +1 more source

Supplementary Figure 4 from RAP80 Acts Independently of BRCA1 in Repair of Topoisomerase II Poison-Induced DNA Damage

, 2023
Junko Iijima, Zhihong Zeng, Shunichi Takeda, Yoshihito Taniguchi   +3 more
openalex   +1 more source

Hydrogels for Cancer Immunotherapy: Strategies From Construction to Application

MedComm, Volume 7, Issue 2, February 2026.
Hydrogels offer an innovative platform for cancer immunotherapy. Through tailorable crosslinking strategies, they form customizable drug delivery platforms that address diverse therapeutic requirements by loading specific immunotherapeutic agents. These systems demonstrate significant clinical potential for precise tumor immunotherapy.
Xiaohua Chen, Shan Wu, Yueyang Zhang, Lilu Feng, Yang Chen, Xuzhao Yang, Ke Men, Jiuqun Zhu, Ming Li   +8 more
wiley   +1 more source

Determining Preclinical Safety of Aclarubicin in Pediatric Malignancies

Pediatric Blood &Cancer, Volume 73, Issue 2, February 2026.
ABSTRACT Background Anthracyclines are among the most effective chemotherapeutic agents used to treat pediatric malignancies. However, their clinical use is limited by dose‐dependent toxicities, particularly cardiotoxicity and secondary malignancies.
Darleen S. Tu, Aaron K. Olson, Kimberly S. Waggie, Nicolas M. Garcia, Virginia J. Hoglund, Stephanie I. Walter, Jenna R. Rosinski, Harini Sadeeshkumar, Radhika Patel, Erolcan Sayar, Michael C. Haffner, Lisa Maves, Jacques Neefjes, Jay F. Sarthy, Elizabeth R. Lawlor, Shireen S. Ganapathi   +15 more
wiley   +1 more source

Binding of ATP to human DNA topoisomerase I resulting in an alteration of the conformation of the enzyme [PDF]

, 1999
Hui‐Jye Chen, Jaulang Hwang
openalex   +1 more source

Fluoroquinolone‐Associated Psychiatric and Ocular Adverse Events: A Disproportionality Analysis Using Real‐World Data From FAERS (2011–2024)

Pharmacology Research &Perspectives, Volume 14, Issue 1, February 2026.
This pharmacovigilance study identifies a wide range of rapid‐onset neuropsychiatric and ocular adverse effects linked to fluoroquinolones (FQ). Disproportionality analysis revealed a disproportionate reporting of suicidal ideation and visual impairment following FQ treatment, emphasizing the urgent need for cautious prescribing and strengthened safety
Hau‐Tak Chau, Ngan Pan Bennett Au
wiley   +1 more source